Molecular markers in blood at birth are linked to later development of acute lymphoblastic leukemia, the most common cancer type that affects children, according to a study published in Molecular Cancer.
Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.
Inflo Health, a leader in AI-driven radiology follow-up care orchestration, announced that it has qualified for the American College of Radiology’s Learning Network Vendor Partner designation on the heels of a successful collaboration that saw East Alabama Medical Center significantly improve recommendations follow-up rates.
The American Cancer Society released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States.
New research on the possibility to kill TNBCs by hijacking signals that normally drive mammary gland involution was released in Nature.
The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.
Continuity of Medicaid coverage increases the survival rates of children and adolescents with cancer, according to research published in JCO Oncology Practice.
A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest.
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center revealed that common breast cancer treatments, including chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors.
Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
